These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. Kiyuna T; Tome Y; Murakami T; Zhao M; Miyake K; Igarashi K; Kawaguchi K; Miyake M; Oshiro H; Higuchi T; Li Y; Dry SM; Nelson SD; Russell TA; Eckardt MA; Singh AS; Kanaya F; Eilber FC; Hoffman RM J Cell Biochem; 2018 Sep; 119(9):7827-7833. PubMed ID: 29932244 [TBL] [Abstract][Full Text] [Related]
7. Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Zhao M; Zhang Y; Nelson SD; Russell TA; Dry SM; Singh AS; Chmielowski B; Li Y; Unno M; Eilber FC; Hoffman RM Cell Cycle; 2017 Jul; 16(13):1288-1294. PubMed ID: 28622068 [TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. Kawaguchi K; Igarashi K; Murakami T; Chmielowski B; Kiyuna T; Zhao M; Zhang Y; Singh A; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM Oncotarget; 2016 Dec; 7(52):85929-85936. PubMed ID: 27835903 [TBL] [Abstract][Full Text] [Related]
9. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277 [TBL] [Abstract][Full Text] [Related]
10. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999 [TBL] [Abstract][Full Text] [Related]